GV, an early-stage corporate venturing subsidiary of internet and technology group Alphabet, has hired Sridhar Ramaswamy as an entrepreneur-in-residence to explore the oncology ecosystem.
Ramaswamy moved from US-based cancer treatment developer Tesaro, where he had been senior vice-president and head of research and early development since 2017.
Prior to Tesaro, Ramaswamy had been an oncologist dedicated to breast cancer, gastrointestinal cancer and leukaemia care for nearly two decades at Massachusetts General Hospital, following stints at Brigham and Women’s Hospital and Dana-Farber Cancer Institute as an attending physician.
Ramaswamy will leverage his medical background to identify biotechnology, healthcare and life sciences investment opportunities.
GV expanded its focus on life sciences in December 2018 by hiring its first entrepreneur-in-residence, Rosana Kapeller, formerly chief scientific officer for biotechnology developer Nimbus Therapeutics.
The unit also appointed David Schenkein, previously CEO of biopharmaceutical company Agios Pharmaceuticals, in February 2019 to oversee life sciences investment initiatives alongside fellow general partners Blake Byers and Krishna Yeshwant.
Ramaswamy should not be confused with namesake Sridhar Ramaswamy, who moved to venture capital firm Greylock Partners in 2018 after more than 15 years at another Alphabet branch, Google.
Photo of Sridhar Ramaswamy courtesy of GV.
